Through a partnership with Philadelphia-based Jefferson Health, Exact Sciences is creating a support framework for a blood-based cancer screening test in development.

“We’re trying to really understand behaviors, attitudes, and potentially fears about this kind of new test and technology before we actually launch it in the marketplace,” said David Harding, senior vice president of Thrive, a subsidiary of the Madison-based diagnostics company.

In a recent interview, he explained that rolling out a new test like this can cause “a lot of confusion” for both doctors and their patients. By simulating aspects of the testing and follow-up process with patients at the health system, the partnership aims to determine what kinds of educational materials, navigational aids and other support should be offered to supplement the test.

Click here to read the full article.